Repaglinide: A pharmacoeconomic review of its use in type 2 diabetes mellitus

PharmacoEconomics

Volumn 22, Issue 6, 2004, Pages 389-411

  Plosker, Greg L ^a   Figgitt, David P ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

Antidiabetic agents; Cost effectiveness; Diabetes mellitus; Meglitinides; Pharmacoeconomics; Repaglinide; Therapeutic use

Indexed keywords

CIMETIDINE; CLARITHROMYCIN; DIGOXIN; ETHINYLESTRADIOL; GEMFIBROZIL; GLIBENCLAMIDE; GLIPIZIDE; GLUCONORM; HEMOGLOBIN A1C; KETOCONAZOLE; METFORMIN PLUS ROSIGLITAZONE; NATEGLINIDE; NIFEDIPINE; ORAL ANTIDIABETIC AGENT; REPAGLINIDE; RIFAMPICIN; ROSIGLITAZONE; SIMVASTATIN; SULFONYLUREA; THEOPHYLLINE; WARFARIN;

BODY WEIGHT; CANADA; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COMORBIDITY; COST EFFECTIVENESS ANALYSIS; DRUG SENSITIVITY; ECONOMIC EVALUATION; HEADACHE; HUMAN; HYPOGLYCEMIA; INDUSTRIALIZATION; INSULIN RELEASE; LIFESPAN; LONG TERM CARE; METABOLIC REGULATION; MONOTHERAPY; MORBIDITY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT COMPLIANCE; PREVALENCE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; REVIEW; SENSITIVITY ANALYSIS; SHORT COURSE THERAPY; SIDE EFFECT; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME; UNITED KINGDOM; UNITED STATES; UPPER RESPIRATORY TRACT INFECTION;

ADMINISTRATION, ORAL; CARBAMATES; CLINICAL TRIALS; COST OF ILLNESS; COST-BENEFIT ANALYSIS; DIABETES MELLITUS, TYPE 2; DRUG INTERACTIONS; ECONOMICS, PHARMACEUTICAL; HUMANS; HYPOGLYCEMIC AGENTS; PIPERIDINES; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS;

EID: 2342501441     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-200422060-00005     Document Type: Review

References (45)

1. Malaisse WJ. Stimulation of insulin release by non-sulfonylurea hypoglycemic agents: the meglitinide family. Horm Metab Res 1995 Jun; 27 (6): 263-6
2. Dornhorst A. Insulinotropic meglitinide analogues. Lancet 2001 Nov 17; 358 (9294): 1709-16
3. Culy CR, Jarvis B. Repaglinide: a review of its therapeutic use in type 2 diabetes mellitus. Drugs 2001; 61 (11): 1625-60
4. Gerich JE. Clinical significance, pathogenesis, and management of postprandial hyperglycemia. Arch Intern Med 2003 Jun 9; 163 (11): 1306-16
5. Bonora E, Muggeo M. Postprandial blood glucose as a risk factor for cardiovascular disease in type II diabetes: the epidemiological evidence. Diabetologia 2001 Dec; 44 (12): 2107-14
6. Avignon A, Radauceanu A, Monnier L. Nonfasting plasma glucose is a better marker of diabetic control than fasting plasma glucose in type 2 diabetes. Diabetes Care 1997 Dec; 20 (12): 1822-6
7. Bastyr III EJ, Stuart CA, Brodows RG, et al. Therapy focused on lowering postprandial glucose, not fasting glucose, may be superior for lowering HbAlc. Diabetes Care 2000 Sep; 23 (9): 1236-41
8. Hanefeld M, Fischer S, Julius U, et al. Risk factors for myocardial infarction and death in newly detected NIDDM: the Diabetes Intervention Study, 11-year follow-up. Diabetologia 1996 Dec; 39 (12): 1577-83
9. Tominaga M, Eguchi H, Manaka H, et al. Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose: the Funagata Diabetes Study. Diabetes Care 1999; 22: 920-4
10. Fuhlendorff J, Rorsman P, Kofod H, et al. Stimulation of insulin release by repaglinde and glibenclamide involves both common and distinct processes. Diabetes 1998 Mar; 47 (3): 345-51
11. Novo Nordisk. Prandin® (repaglinide) prescribing information [revised package insert]. Princeton (NJ): 2003 Aug 5
12. Davies MJ. Insulin secretagogues. Curr Med Res Opin 2002; 18 Suppl. 1: s22-30
13. Malaisse WJ. Mechanism of action of a new class of insulin secretagogues. Exp Clin Endocrinol Diabetes 1999; 107 Suppl. 4: S140-3
14. Novo Nordisk Limited. NovoNorm® (repaglinide) summary of product characteristics (version 5) [online]. Available from URL: www.nononordisk.co.uk [Accessed 2003 Feb 23]
15. Amos AF, McCarty DJ, Zimmet P. The rising global burden of diabetes and its complications: estimates and projections to the year 2010. Diabet Med 1997; 14 Suppl. 5: S7-S84
16. Gadsby R. Epidemiology of diabetes. Adv Drug Deliv Rev 2002 Nov 5; 54 (9): 1165-72
17. Bagust A, Hopkinson PK, Maslove L, et al. The projected health care burden of type 2 diabetes in the UK from 2000 to 2060. Diabet Med Suppl 2002 Jul; 19 Suppl. 4: 1-5
18. American Diabetes Association. Economic costs of diabetes in the US in 2002. Diabetes Care 2003 Mar; 26 (3): 917-32
19. Rathmann W, Haastert B, Icks A, et al. High prevalence of undiagnosed diabetes mellitus in southern Germany: target populations for efficient screening. The KORA survey 2000. Diabetologia 2003 Feb; 46 (2): 182-9
20. Saydah SH, Eberhardt MS, Loria CM, et al. Age and the burden of death attributable to diabetes in the United States. Am J Epidemiol 2002 Oct; 156 (8): 714-9
21. Jönsson B, CODE-2 Advisory Board. Revealing the cost of Type II diabetes in Europe. Diabetologia 2002 Jul; 45 (7): S5-12
22. Redekop WK, Koopmanschap MA, Rutten GE, et al. Resource consumption and costs in Dutch patients with type 2 diabetes mellitus: results from 29 general practices. Diabet Med 2002 Mar; 19 (3): 246-53
23. Lucioni C, Garancini MP, Massi-Benedetti M, et al. The costs of type 2 diabetes mellitus in Italy: a CODE-2 sub-study. Treat Endocrinol 2003; 2 (2): 121-33
24. Williams R, Van Gaal L, Lucioni C. Assessing the impact of complications on the costs of type II diabetes. Diabetologia 2002 Jul; 45 (7): S13-7
25. FXConverter - 164 currency converter [online]. Available from URL: http://www.oanda.com/convert/classic [Accessed 2003 Nov 28]
26. Brandle M, Zhou H, Smith BRK, et al. The direct medical cost of type 2 diabetes. Diabetes Care 2003 Aug; 26 (8): 2300-4
27. Brown JB, Pedula KL, Bakst AW. The progressive cost of complications in type 2 diabetes mellitus. Arch Intern Med 1999 Sep 13; 159 (16): 1873-80
28. Caro JJ, Ward AJ, O'Brien JA. Lifetime costs of complications resulting from type 2 diabetes in the U.S. Diabetes Care 2002 Mar; 25 (3): 476-81
29. O'Brien JA, Patrick AR, Caro J. Estimates of direct medical costs for microvascular and macrovascular complications resulting from type 2 diabetes mellitus in the United States in 2000. Clin Ther 2003 Mar; 25 (3): 1017-38
30. de Grauw WJ, van de Lisdonk EH, Behr RR, et al. The impact of type 2 diabetes mellitus on daily functioning. Fam Pract 1999 Apr; 16 (2): 133-9
31. Westaway MS, Rheeder P, Gumede T. The effect of type 2 diabetes mellitus on health-related quality of life (HRQOL). Curationis 2001 Mar; 24 (1): 74-8
32. Redekop WK, Koopmanschap MA, Rutten GEHM, et al. Health-related quality of life and treatment satisfaction in Dutch patients with type 2 diabetes. Diabetes Care 2002 Mar; 25 (3): 458-63
33. Landgraf R. Meglitinide analogues in the treatment of type 2 diabetes mellitus. Drugs Aging 2000 Nov; 17 (5): 411-25
34. Hatorp V. Clinical pharmacokinetics and pharmacodynamics of repaglinide. Clin Pharmacokinet 2002; 41 (7): 471-83
35. Chuang LM, Tai TY, Juang JH, et al. Effect of a prandial glucose regulator (NovoNorm®) at two doses (0.5mg and 2.0mg) on glycemic control in type 2 diabetes in Taiwan. JAMA SE Asia 1999; 15 (1): 22-5
36. Goldberg RB, Einhorn D, Lucas CP, et al. A randomized placebo-controlled trial of repaglinide in the treatment of type 2 diabetes. Diabetes Care 1998 Nov; 21 (11): 1897-903
37. Jovanovic L, Dailey III G, Huang WC, et al. Repaglinide in type 2 diabetes: a 24-week, fixed-dose efficacy and safety study. J Clin Pharmacol 2000 Jan; 40 (1): 49-57
38. Wolffenbuttel BH, Landgraf R. A 1-year multicenter randomized double-blind comparison of repaglinide and glyburide for the treatment of type 2 diabetes: Dutch and German Repaglinide Study Group. Diabetes Care 1999 Mar; 22 (3): 463-7
39. Marbury T, Huang WC, Strange P, et al. Repaglinide versus glyburide: a one-year comparison trial. Diabetes Res Clin Pract 1999 Mar; 43 (3): 155-66
40. Landgraf R, Bilo HJ, Muller PG. A comparison of repaglinide and glibenclamide in the treatment of type 2 diabetic patients previously treated with sulphonylureas. Eur J Clin Pharmacol 1999 May; 55 (3): 165-71
41. Madsbad S, Kilhovd B, Lager I, et al. Comparison between repaglinide and glipizide in type 2 diabetes mellitus: a 1-year multicentre study. Diabet Med 2001 May; 18 (5): 395-401
42. Novo Nordisk Pharmaceuticals Inc. Repaglinide (Prandin®) clinical overview. 2003 Oct. (Unpublished data on file)
43. U.K. Prospective Diabetes Study (UKPDS) Group. U.K. Prospective Diabetes Study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. Diabetes 1995 Nov; 44 (11): 1249-58
44. Derosa G, Mugellini A, Ciccarelli L, et al. Comparison of glycaemic control and cardiovascular risk profile in patients with type 2 diabetes during treatment with either repaglinide or metformin. Diabetes Res Clin Pract 2003 Jun; 60 (3): 161-9
45. Moses R, Slobodniuk R, Boyages S, et al. Effect of repaglinide addition to metformin monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care 1999 Jan; 22 (1): 119-24